January 13, 2026 -
Pittsburgh, PA, USA – January 13, 2026 – MolecuLight Corp. and MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria and digital wound measurement, today announced that it has filed a complaint with the United States International Trade Commission (ITC) requesting
… Read MoreDecember 16, 2025 -
Tissue Analytics moves toward a unified, AI-powered imaging experience that seamlessly connects data from point-of-care devices to EHR workflows
PITTSBURGH, PA – Dec. 16, 2025 – Net Health today announced the platform integration of MolecuLight with Tissue Analytics, its AI-powered mobile wound imaging and analytics solution. This enables
… Read MoreDecember 9, 2025 -
Streamlined integration enhances wound care by combining bacterial detection, digital wound measurements, and thermal imaging with direct Oracle Health Foundation EHR connectivity
Pittsburgh, USA, December 9, 2025 – MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment and an Oracle partner, today announced the
… Read MoreNovember 13, 2025 -
Pittsburgh, USA – November 13, 2025 – MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment, is proud to announce the publication of a landmark international consensus report, developed by leading experts in wound care and surgery from across the United States. The report,
… Read MoreAugust 27, 2025 -
PITTSBURGH, USA and TAIPEI, TAIWAN, August 27, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, together with its Taiwanese distributor, Healtdeva Company Ltd., today announced the publication of the largest-ever randomized controlled trial (RCT) on its technology. Independently conducted and published
… Read MoreJuly 18, 2025 -
Pittsburgh, USA – July 18, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, today announced its participation in the National Medical Association (NMA) Annual Convention and Scientific Assembly, being held from July 19-23, 2025, in Chicago, IL. Attendees are invited to
… Read MoreJuly 10, 2025 -
Pittsburgh, USA – July 10, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, today announced the appointment of Dr. Julia Wright, MD, FACP, as its new Chief Medical Officer (CMO). Dr. Wright, an exceptionally respected physician with a distinguished 25-year career
… Read MoreJune 26, 2025 -
Pittsburgh, USA – June 26, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a landmark systematic review by researchers at Trinity College Dublin and the Royal College of Surgeons in Ireland (RCSI). Titled “The Clinical Utility
… Read MoreJune 21, 2025 -
Pittsburgh, USA – June 21, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, is proud to showcase its presence at the St. Louis Wound & Vascular Symposium, being held today, Saturday, June 21, 2025, in St. Louis, MO. Attendees are invited to experience firsthand
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2026
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.